Lb Pharmaceuticals Inc (LBRX) Stock Price, Quote & News

Company Profile

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 605 0300

Website: lbpharma.us

Address:

One Pennsylvania Plaza, Suite 1025, New York, United States

Doozio Aug. 7 at 5:01 PM

@Stocktwits board please. Yo ain’t bored no moar as $LBRX finally has one!

1 · Reply

efficiency Aug. 6 at 3:39 PM

$LBRX Trend measures 192% in 200 days. Potent.

0 · Reply

Stairmaster Aug. 3 at 5:29 PM

$LBRX

0 · Reply

Roronao Jul. 30 at 11:28 PM

$LBRX $BRZE watchlist-1

0 · Reply

STACKD0E Jul. 29 at 3:10 PM

$LBRX 👁️

1 · Reply

Quantumup Jul. 27 at 11:36 AM

Stifel on $MPLT (Buy-$36) said -- We're reiterating our Buy rating on MPLT following the positive ph2 schizophrenia data for their M1/M4 agonist. $BMY $LBRX ABBV NBIX RVPH VNDA NMRA OTSKY TEVA Here's what else Stifel had to say in its note to investors: https://x.com/Quantumup1/status/2081704930721649058?s=20

0 · Reply

Quantumup Jul. 24 at 11:53 AM

H.C. Wainwright y'day reiterated $LBRX Buy-$45 and said -- LB-102 pivotal confirmatory schizophrenia trial timeline accelerated, with faster release of top-line data anticipated. $MPLT $BMY ABBV NMRA VNDA H.C. Wainwright added—LB Pharmaceuticals announced that based on enrollment projections, it now expects to report top-line results from the pivotal Phase 3 NOVA-2 clinical trial of LB-102 in patients with schizophrenia in 1H27 and to schedule a pre-NDA meeting with the FDA thereafter, during 2H27, to discuss the requirements for completion of the LB-102 New Drug Application (NDA) submission for approval of this candidate in treatment of schizophrenia. In our view, the shorter timeline to top-line data may facilitate regulatory submission in 1H28 and potential approval and market entry earlier in 2029 than we currently project. We await the top-line data and feedback from the pre-NDA meeting ahead of advancing the timing of sales initiation in our model.

0 · Reply

Quantumup Jul. 24 at 11:31 AM

Canaccord⬆️ $MPLT to $43 from $35, reiterated Buy and said MPLT expects top-line data from its Ph2 ZEPHYR trial for ML-007C-MA for schizophrenia in mid-August. $BMY $LBRX ABBV NBIX RVPH VNDA NMRA OTSKY TEVA Canaccord added that it believes solid ZEPHYR data could make the shares blow through even higher levels despite the stock's recent strength.

0 · Reply